在冠状动力反应性测试中对静脉输入与冠状动脉内腺的评估
Fazal Dalal1, Yissela Escobedo2, Jose Emilio Exaire2
1Department of Internal Medicine, Baylor Scott and White, Temple, Texas.
The American journal of cardiology
|October 25, 2024
概括
冠心内 (IC) 腺提供类似于静脉内 (IV) 腺的结果,用于冠心反应性测试 (CRT),使用玻尿酸热稀释. 这表明IC腺是评估冠状动脉流量储备 (CFR) 和微循环阻力指数 (IMR) 的可行的替代方案.
科学领域:
- 心脏病学 心脏病学
- 心血管生理学心血管生理学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 冠状动脉流量储备 (CFR) 和微循环阻力指数 (IMR) 对于诊断非阻塞性冠状动脉疾病中心痛至关重要.
- 之前的研究确定了静脉注射 (IV) 和冠内 (IC) 腺之间的等价性,用于通过分数流量储备来评估表心缺血症.
- 在冠状动脉反应性测试 (CRT) 中,IC与IV腺在达到最大高血压时的比较疗效仍未得到解决.
研究的目的:
- 为了研究在CRT期间IC和IV腺素的管理之间的相关性.
- 评估IC腺是否可以作为玻尿酸热稀释CRT中的IV腺的替代品.
- 为了比较来自IC和IV腺方法的CFR和IMR值.
主要方法:
- 对CRT数据和患者人口统计数据进行了回顾性分析.
- 在一组患者中,使用IC和IV腺素诱导最大的高血压.
- 统计分析包括线性回归,ANOVA,威尔科克森测试和布兰德-阿尔特曼分析,以比较CFR和IMR.
主要成果:
- 分析了62名患者 (平均年龄为60.5岁,72%为女性).
- CFR值为3.12 (IC) 和2.71 (IV),而IMR值为28.23 (IC) 和22.27 (IV).
- CFR和IMR都显示了IC和IV腺之间良好的相关性 (CFR的R2=0.50,IMR的R2=0.33),没有显著的方法内部变异性.
结论:
- 在玻尿酸热稀释CRT中,IC腺与IV腺在CFR和IMR测量方面表现出强烈的相关性.
- 这些发现支持IC腺作为CRT的IV腺的潜在替代品.
- 这为临床医生管理患有心痛和非阻塞性冠状动脉疾病的患者提供了有价值的选择.
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic studies
3
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
01:28Imaging Studies for Cardiovascular System V: CT
3
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
3
01:28Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
460
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
460
01:19Acute Coronary Syndrome II: Pathophysiology and clinical manifestations
3
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
3
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1